Amisulpride in Schizophrenic Acute Phase Patients

Phase 4CompletedNCT00436371

Sanofi50 enrolled

Overview

To collect the safety and response of using Amisulpride in acute schizophrenic patients

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

AmisulprideDRUG

Oral tablets

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient diagnosed as Diagnostic and Statistical Manual of Mental Disorder, 4th edition, as paranoid, disorganized or undifferentiated type of schizophrenia in acute episode Exclusion Criteria: * Patients previously treated with amisulpride * Patients have comorbidity which may interfere with the treatment or follow-up * Patients currently taking depot antipsychotics (at least 30 days washout period is needed) * Patients currently/ or recently (\< 3 months) withdrawn from drug or alcohol abuse * Pregnant or lactation The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis

Hong Kong, Hong Kong

Outcomes

Primary Outcomes

Adverse events

Time frame: all across the study

Secondary Outcomes

Clinical Global Impressions

Time frame: All accross the study

Patient compliance

Time frame: all across the study

Percentage of patient completing treatment

Time frame: all across the study

Changes in body weight

Time frame: At baseline and day 84

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.